Xeris Biopharma Holdings, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Dec'23

Net Sales

71.54

60.12

60.10

54.27

48.06

40.64

44.39

Other Operating Income

0.00

Total Operating income

71.54

60.12

60.10

54.27

48.06

40.64

44.39

Raw Material Cost

14.61

11.44

12.19

16.30

10.50

8.68

10.28

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

7.36

7.30

7.70

7.79

7.96

7.03

7.02

Selling and Distribution Expenses

44.39

44.02

40.14

44.97

39.99

38.38

37.57

Other Expenses

0.07

0.04

-0.16

-0.19

-0.22

0.08

-0.06

Total Expenditure (Excl Depreciation)

67.06

63.21

58.42

67.16

56.25

54.88

54.23

Operating Profit (PBDIT) excl Other Income

4.5

-3.1

1.7000000000000002

-12.9

-8.2

-14.2

-9.8

Other Income

0.95

1.18

0.91

1.20

1.29

1.92

1.11

Operating Profit (PBDIT)

8.59

1.23

5.72

-8.57

-3.74

-9.11

-5.47

Interest

7.36

7.30

7.70

7.79

7.96

7.03

7.02

Exceptional Items

0.00

0.42

0.60

0.68

2.13

Gross Profit (PBDT)

56.93

48.68

47.91

37.96

37.56

31.96

34.11

Depreciation

3.16

3.14

3.13

3.12

3.15

3.21

3.26

Profit Before Tax

-1.93

-9.22

-5.11

-19.06

-14.26

-18.67

-13.63

Tax

0.00

-3.32

0.75

0.31

-0.24

Provisions and contingencies

0.00

Profit After Tax

-1.93

-9.22

-5.11

-15.74

-15.01

-18.98

-13.39

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-1.93

-9.22

-5.11

-15.74

-15.01

-18.98

-13.39

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-1.93

-9.22

-5.11

-15.74

-15.01

-18.98

-13.39

Equity Capital

0.00

Face Value

0.0

Reserves

-19.30

-35.13

-29.61

-28.32

-19.29

-9.18

-6.78

Earnings per share (EPS)

-0.01

-0.06

-0.03

-0.11

-0.1

-0.14

-0.1

Diluted Earnings per share

-0.01

-0.06

-0.03

-0.11

-0.1

-0.14

-0.1

Operating Profit Margin (Excl OI)

6.27%

-5.14%

2.79%

-23.76%

-17.03%

-35.05%

-22.17%

Gross Profit Margin

1.73%

-10.11%

-3.29%

-29.37%

-23.1%

-38.04%

-23.35%

PAT Margin

-2.7%

-15.34%

-8.51%

-29.0%

-31.22%

-46.71%

-30.16%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Jun 2025 is 18.97% vs 0.00% in Mar 2025

Consolidate Net Profit

QoQ Growth in quarter ended Jun 2025 is 79.35% vs -80.39% in Mar 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Jun 2025 is 7,500.00% vs -97.92% in Mar 2025

Interest

QoQ Growth in quarter ended Jun 2025 is 1.37% vs -5.19% in Mar 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

Compare Quarterly Results Of Xeris Biopharma Holdings, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(USD)

Change(%)

Net Sales

71.54

0.22

71.32

32,418.18%

Other Operating Income

0.00

Total Operating income

71.54

0.22

71.32

32,418.18%

Raw Material Cost

14.61

1.49

13.12

880.54%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

7.36

0.00

7.36

Selling and Distribution Expenses

44.39

12.56

31.83

253.42%

Other Expenses

0.07

2.59

-2.52

-97.30%

Total Expenditure (Excl Depreciation)

67.06

39.93

27.13

67.94%

Operating Profit (PBDIT) excl Other Income

4.48

-39.71

44.19

111.28%

Other Income

0.95

3.59

-2.64

-73.54%

Operating Profit (PBDIT)

8.59

-34.62

43.21

124.81%

Interest

7.36

0.00

7.36

Exceptional Items

0.00

Gross Profit (PBDT)

56.93

-1.27

58.20

4,582.68%

Depreciation

3.16

1.49

1.67

112.08%

Profit Before Tax

-1.93

-36.12

34.19

94.66%

Tax

0.00

0.85

-0.85

-100.00%

Provisions and contingencies

0.00

Profit After Tax

-1.93

-16.55

14.62

88.34%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-1.93

-16.55

14.62

88.34%

Share in Profit of Associates

0.00

Minority Interest

0.00

-20.41

20.41

100.00%

Other related items

0.00

Consolidated Net Profit

-1.93

-36.97

35.04

94.78%

Equity Capital

0.00

Face Value

0.00

Reserves

-19.30

-1,002.50

983.20

98.07%

Earnings per share (EPS)

-0.01

-0.13

0.12

92.31%

Diluted Earnings per share

-0.01

-0.13

0.12

92.31%

Operating Profit Margin (Excl OI)

6.27%

-17,967.87%

0.00

17,974.14%

Gross Profit Margin

1.73%

-15,667.87%

0.00

15,669.60%

PAT Margin

-2.70%

-7,489.59%

0.00

7,486.89%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 7.15 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 18.97% vs 0.00% in Mar 2025

YoY Growth in quarter ended Jun 2025 is 48.65% vs 26.58% in Jun 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit -0.19 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 79.35% vs -80.39% in Mar 2025

YoY Growth in quarter ended Jun 2025 is 87.33% vs 24.24% in Jun 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 0.76 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 7,500.00% vs -97.92% in Mar 2025

YoY Growth in quarter ended Jun 2025 is 252.00% vs 60.32% in Jun 2024

Quarterly - Interest

Interest 0.74 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 1.37% vs -5.19% in Mar 2025

YoY Growth in quarter ended Jun 2025 is -7.50% vs 23.08% in Jun 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 6.27%

in Jun 2025

Figures in %

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

YoY Growth in quarter ended Jun 2025 has improved from Jun 2024